2008年，厦门大学生物科学专业，学士学位；
2013年，厦门大学细胞与分子生物学专业，博士学位；
2015-2018年，厦门大学生命科学学院，工程师；
2019年-2024年，厦门大学生命科学学院，助理教授
2025年至今，厦门大学生命科学学院，副教授
B.S. 2008, Xiamen University, Life Science;
Ph.D. 2013, Xiamen University, Cellular and Molecular Biology;
Engineer, Xiamen University, 2015-2019;
Assistant Professor, School of Life Sciences, Xiamen University, 2019-2024;
Associate Professor, School of Life Sciences, Xiamen University, 2025 to Present.

李莉博士的研究方向主要分为以下两个方面：
（1）活性天然产物药物的发现和机制研究
天然产物具有结构多样性和复杂性，是新靶点、新机制以及创新药物的绝佳来源。我们通过微生物天然产物分离以及合成生物学改造，从中发现具有生物活性的、结构新颖的天然产物，并应用化学蛋白质组学手段，解析其作用靶点和分子机制。
（2）新颖药物靶标的功能及分子调控机制研究
从重大疾病的研究入手，发现潜在的药物靶标，通过构建细胞或生化的筛选平台，获得特异性靶向潜在靶标的活性小分子，从而验证靶标可行性，同时为疾病治疗提供创新药物先导物。
Our research lies in two major areas:
(1) Discovery and mechanistic research of bioactive natural products
Natural products have long been considered as valuable source for drug development. Using traditional isolation and biosynthetic approaches, we aim to discover natural products with novel structural basis and biological activities; We further identify their direct targets and dissect the detailed molecular mechanisms by chemoproteomic approaches.
(2) Functional and regulatory mechanism study on potential therapeutic targets
We screen bioactive small molecules targeting potential therapeutic targets (such as untargeted kinases, epigenetic enzymes and so on), offer preclinical proof of concepts for therapeutic targeting these targets and provide lead compounds with novel structures.

代表性论文(^# co-first author, ^* Corresponding author):

长期开展多学科交叉的药物化学生物学研究，聚焦以活性天然分子为化学工具，发现疾病相关的药物新靶标，解析调控新机制，并推动先导化合物的确证和临床转化。研究工作在国际期刊发表论文37篇，其中以第一、共一或共同通讯作者身份在Nat. Chem. Biol.、Cell Rep. Med.、Cell Chem. Biol.、Acta Pharm. Sin. B、Signal Transduct. Target. Ther.等高水平期刊发表研究论文。同时，申请人作为主要发明人申请发明专利6项，获得4项专利的15件授权，其中2项实现技术转让。
[1] Su N, Lian W, Zhang B, Tian Y, Li L, Chen Y, Zhi X, Zeng T, Wu Q, Chen L, Zhou D, Wang HR, Cheng SC, Li L^*, Deng X^*. Inhibiting NEDD4 in triple-negative breast cancer cells reprograms tumor immune microenvironment via the β-TrCP/YAP/ECM axis. Cell Rep Med. 2025 Oct 21;6(10):102420.
[2] Li L^*，^#, Wang Y, Wang Y, Li X, Deng Q, Gao F, Lian W, Li Y, Gui F, Wei Y, Zhu SJ, Yun CH, Zhang L, Hu Z, Xu Q, Wu X, Chen L, Zhou D, Zhang J, Xia F^*, Deng X^*. Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification. Acta Pharm Sin B. 2025 Jan;15(1):409-423.
[3] Wu Z, Liu X, Yan XE, Wu X, Huang W, Li J, Xiu Y, Lv C, Sun C, Wang Z, Xu G, Wu X, Hu Z, Huang H, Huang X, Zhang J^*, Yun CH^*, Li L^*, Deng X^*. Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations. J Med Chem. 2025 Sep 25;68(18):19205-19228.
[4] Gao F, Wu Z, Lin A, Wu X, Zhang B, Liu L, Lu Y, Geng S, Huang Z, Chen Y, Zhang J, Li L^*, Deng X^*. Discovery of an ALK degrader for lorlatinib-resistant compound mutations. Eur J Med Chem. 2025 Oct 15;296:117835.
[5] Zeng J, Li L^#, Sun C, Sheng S, Tan Y, Chen J, Xia F, Deng X^*, Xu X^*. Structure-Based Discovery of Active Pan-KRas Inhibitors Targeting G12D Mutants by Enhanced Sampling Simulations. J Phys Chem B. 2025 Sep 18;129(37):9283-9292.
[6] Chu Y, Chen S, Yang M, Chen Y, Fang H, Huang P, Xie Y, Sun C, Chen Y, Zhang B, Li L, Mu H, Song D, Cheng W, Wang C, Jiang W, Xu X, He Z, Chen S, Liu M, Ma J, Yang M, Cao J, Gao J, Shen J, Zhang L, Bai Y, Liu Z, Chen J, Dai S, Zeng YA, Zhao Y, Zhou H, Chen C, Ru H, Tan L, Chi X, Wang F, Gao D, Lin M, Deng X, Jiang H. A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. Nat Biotechnol. 2025 Sep 10. doi: 10.1038/s41587-025-02793-8
[7] Wu Z, Zhu X, Hong A, He G, Wang Z, Xu Q, Hu Z, Wu X, Wang Y, Chen Q, Zhao X, Li L^*, Deng X^*. Discovery of urea-based pleuromutilin derivatives as potent gram-positive antibacterial agents. Bioorg Chem. 2023 Jul;136:106547.
[8] Li L, Wang Y, Chen N, Li X, Li H, Jin L, Ou Y, Kong XJ, Cao S, Xu Q, Wu X, Han J, Deng X. Exploring Diversity through Dimerization in Natural Products by a Rational Tandem Mass-Based Molecular Network Strategy. Org Lett. 2023 Jun 9;25(22):4016-4021.
[9] Zhu X, Hong A, Sun X, Wang W, He G, Luo H, Wu Z, Xu Q, Hu Z, Wu X, Huang D, Li L^*, Zhao X^*, Deng X^*. Nigericin is effective against multidrug resistant gram-positive bacteria, persisters, and biofilms. Front Cell Infect Microbiol. 2022 Dec 20;12:1055929.
[10] Su J, Zheng J, Huang W, Zhang Y, Lv C, Zhang B, Jiang L, Cheng T, Yuan Q, Xia N, Zhang J, Li L^*, Li L^*, Deng X^*. PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron. Signal Transduct Target Ther. 2022 May 24;7(1):167.
[11] Wang Y^#, Zhang L^#, Wei Y^#, Huang W^#, Li L^#, Wu AA, Dastur A, Greninger P, Bray WM, Zhang CS, Li M, Lian W, Hu Z, Wang X, Liu G, Yao L, Guh JH, Chen L, Wang HR, Zhou D, Lin SC, Xu Q, Shen Y, Zhang J, Jurica MS, Benes CH, Deng X^*. Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8.
[12] Li Y^#, Liu Z^#, Li L^#, Lian W, He Y, Khalil E, Mäkilä E, Zhang W, Torrieri G, Liu X, Su J, Xiu Y, Fontana F, Salonen J, Hirvonen J, Liu W, Zhang H^*, Santos HA^*, Deng X^*. Tandem-Mass-Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition. Adv Sci (Weinh) . 2020 Jun 23;7(15):2001129.
[13] Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y, Li X, Miao X, Li S, Mi X, Zhang J, Li L, Wei G, Xu ZX, Gao X, Huang C, Wei Z, Goding CR, Wang P, Deng X, Cui R. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell. 2019 Feb 21;176(5):1113-1127.e16.
[14] Li L, Liu Y, Chen HZ, Li FW, Wu JF, Zhang HK, He JP, Xing YZ, Chen Y, Wang WJ, Tian XY, Li AZ, Zhang Q, Huang PQ, Han J, Lin T, Wu Q. Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. Nat Chem Biol. 2015 May;11(5):339-46.
[15] Chen HZ^#, Liu QF^#, Li L^#, Wang WJ, Yao LM, Yang M, Liu B, Chen W, Zhan YY, Zhang MQ, Cai JC, Zheng ZH, Lin SC, Li BA, Wu Q. The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating Wnt signalling. Gut. 2012 May;61(5):714-24.

荣誉、奖励及参加学术团体的情况:

福建省自然科学一等奖，2017年